Today (July 16, 2012), the U.S. Food and Drug Administration approved Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners. Truvada, taken daily, is to be used for…
FDA Advisory Committees to Examine a Number of HIV Issues in May
April 18, 2012 • 1 comment • By Richard Klein, Office of Special Health Issues, Food and Drug Administration
The U.S. Food and Drug Administration (FDA) has three important advisory committee meetings scheduled in May that may impact HIV prevention, detection, and treatment. On May 10, 2012, FDA’s Antiviral Advisory Committee will discuss expanding the indication of Truvada (emtricitabine/tenofovir disoproxil fumarate) tablet, made by Gilead Sciences, Inc., to include use for Pre-Exposure Prophylaxis (PrEP),…
Conversation from CROI: Dr. Jonathan Mermin on PrEP and an AIDS-free Generation
March 20, 2012 • 0 comments • By Miguel Gomez, Director, AIDS.gov, and Senior Communications Advisor, Office of HIV/AIDS Policy, U.S. Department of Health and Human Services
At the recent 19th Conference on Retroviruses and Opportunistic Infections (CROI), Dr. Ron Valdiserri, Deputy Assistant Secretary of Health for Infectious Diseases, spoke with Dr. Jonathan Mermin, Director of CDC’s Division of HIV/AIDS Prevention. They discussed some of the significant findings from the conference including advances related to pre-exposure prophylaxis (PrEP) and the growing discussions…
Using Pre-Exposure Prophylaxis (PrEP) as a Prevention Tool for MSM: The Promise Comes with Challenges
February 27, 2011 • 5 comments • By Ronald Valdiserri, M.D., M.P.H., Deputy Assistant Secretary for Health, Infectious Diseases, and Director, Office of HIV/AIDS Policy, U.S. Department of Health and Human Services
On Saturday, February 26th, I attended a day-long meeting organized by the Centers for Disease Control and Prevention (CDC) and hosted by the Fenway Community Health Center in Boston. The theme of the meeting was “Moving forward with PrEP Implementation.” Meeting participants included researchers involved in the original iPrEX study and other ongoing HIV prevention…
NIH-Funded Study Finds Daily Dose of Antiretroviral Drug Reduces Risk of HIV
November 23, 2010 • 2 comments • By Jeffrey S. Crowley, M.P.H., Director, Office of National AIDS Policy
Cross-posted from Office of National AIDS Policy Blog
Cross-posted from Office of National AIDS Policy Blog
Today, the New England Journal of Medicine published research findings from the iPrEx study funded by the National Institutes of Health (NIH) and the Bill and Melinda Gates Foundation testing the efficacy of pre-exposure prophylaxis (PrEP). The study is a major step forward in our ability to prevent new HIV infections. The study found that…
President Obama Welcomes New HIV Prevention Research Results
November 23, 2010 • 7 comments • By AIDS.gov
Cross-posted from The White House, Office of the Press Secretary
Cross-posted from The White House, Office of the Press Secretary
WASHINGTON, D.C. – Today, the National Institutes of Health announced findings on recent HIV prevention research. The study finds that a daily dose of an oral antiretroviral drug taken by HIV-negative gay and bisexual men reduced the risk of acquiring HIV infection by 43.8 percent, and had even higher rates of effectiveness, up to 73…
Interview with Ernest Hopkins and Bob Grant about Pre-exposure Prophylaxis (PrEP)
August 6, 2010 • 1 comment • By Miguel Gomez, Director, AIDS.gov, and Senior Communications Advisor, Office of HIV/AIDS Policy, U.S. Department of Health and Human Services
Recently I sat down with Ernest Hopkins, Legislative Director at the San Francisco AIDS Foundation , and Bob Grant, M.D.,M.P.H. , Senior Investigator at the Gladstone Institute at University of California San Francisco , to talk about pre-exposure prophylaxis (PrEP). Here is a video from our conversation.